Gastroenterology Clinics of North America

Journal Information
ISSN / EISSN : 0889-8553 / 1558-1942
Published by: Elsevier BV (10.1016)
Total articles ≅ 2,914
Current Coverage
SCOPUS
SCIE
MEDICUS
MEDLINE
PUBMED
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Gastroenterology Clinics of North America, Volume 50, pp 489-503; https://doi.org/10.1016/j.gtc.2021.04.001

Abstract:
Irritable bowel syndrome (IBS) prevalence rates are based on diagnostic criteria, the basis for case definitions. Diagnostic criteria have a substantial impact on prevalence rates, which are significant for understanding burden of disease, comparing global subpopulations, generating pathophysiologic research, allocating of health care and research resources, and incentivizing and prioritizing new treatments. There are substantial methodological pitfalls in epidemiologic research, so determining regional and global IBS prevalence rates is problematic. The Rome Foundation Global Epidemiology Study was designed to resolve these problems and achieve more valid results. The results of this study are presented in detail; future directions are discussed.
Andrea McGowan,
Gastroenterology Clinics of North America, Volume 50, pp 595-610; https://doi.org/10.1016/j.gtc.2021.03.007

Abstract:
Irritable bowel syndrome affects 10% to 15% of the population, and up to 90% of patients with irritable bowel syndrome exclude certain foods to improve their gastrointestinal symptoms. Although focused dietary restrictions are a normal, adaptive response, restrictions can spiral out of control and result in maladaptive restriction. Dietary therapies are rapidly becoming first-line treatment of irritable bowel syndrome, and gastroenterologists need to be aware of red flag symptoms of maladaptive eating patterns and the negative effects of prescribing restrictive diets. There is also growing awareness of the association between eating disorders and gastrointestinal symptoms, including irritable bowel syndrome symptoms.
Joy J. Liu,
Gastroenterology Clinics of North America, Volume 50, pp 639-653; https://doi.org/10.1016/j.gtc.2021.04.004

Abstract:
Irritable bowel syndrome with constipation is a common disorder that significantly impairs quality of life. There are now multiple classes of therapeutics that have been shown via rigorous clinical testing to improve the abdominal and bowel symptoms attributed to irritable bowel syndrome with constipation. These include the secretagogues (lubiprostone, linaclotide, plecanatide, tenapenor) and the prokinetic agent tegaserod. This article highlights the pivotal evidence for these agents and most recent treatment guidance from the major North American gastroenterological societies. When pharmaceuticals are used, a patient-specific approach based on efficacy, safety, tolerability, access, and affordability is recommended.
William D. Chey
Gastroenterology Clinics of North America, Volume 50; https://doi.org/10.1016/s0889-8553(21)00690-7

Back to Top Top